JP2009515831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515831A5 JP2009515831A5 JP2008537233A JP2008537233A JP2009515831A5 JP 2009515831 A5 JP2009515831 A5 JP 2009515831A5 JP 2008537233 A JP2008537233 A JP 2008537233A JP 2008537233 A JP2008537233 A JP 2008537233A JP 2009515831 A5 JP2009515831 A5 JP 2009515831A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antigens
- immunogenic composition
- combination
- pestis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 370
- 102000036639 antigens Human genes 0.000 claims 370
- 108091007433 antigens Proteins 0.000 claims 370
- 230000002163 immunogen Effects 0.000 claims 54
- 241000124008 Mammalia Species 0.000 claims 9
- 230000028993 immune response Effects 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 101100421109 Yersinia pestis secM gene Proteins 0.000 claims 5
- 101100493693 Yersinia pestis bamC gene Proteins 0.000 claims 4
- 101100116909 Yersinia pestis djlA gene Proteins 0.000 claims 4
- 101100294224 Yersinia pestis nlpI gene Proteins 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 101100381447 Yersinia pestis bamA gene Proteins 0.000 claims 3
- 101100440427 Yersinia pestis coaE gene Proteins 0.000 claims 3
- 101100281900 Yersinia pestis fyuA gene Proteins 0.000 claims 3
- 101100220525 Yersinia pestis groEL gene Proteins 0.000 claims 3
- 101100188657 Yersinia pestis ompA gene Proteins 0.000 claims 3
- 101100060882 Yersinia pestis pla gene Proteins 0.000 claims 3
- 101100475179 Yersinia pestis rpsC gene Proteins 0.000 claims 3
- 101100093726 Yersinia pestis rpsD gene Proteins 0.000 claims 3
- 101100256513 Yersinia pestis secB gene Proteins 0.000 claims 3
- 101100478915 Yersinia pestis surA gene Proteins 0.000 claims 3
- 101100118435 Yersinia pestis tufA gene Proteins 0.000 claims 3
- -1 YPO0501 Proteins 0.000 claims 2
- 101100170819 Yersinia pestis dnaK gene Proteins 0.000 claims 2
- 101100064180 Yersinia pestis dsbA gene Proteins 0.000 claims 2
- 101100393774 Yersinia pestis hemL gene Proteins 0.000 claims 2
- 101100126385 Yersinia pestis ispD gene Proteins 0.000 claims 2
- 101100472136 Yersinia pestis rplI gene Proteins 0.000 claims 2
- 101100365859 Yersinia pestis skp gene Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 101100370051 Yersinia pestis tolB gene Proteins 0.000 claims 1
- 101100207359 Yersinia pestis tpx gene Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73018205P | 2005-10-25 | 2005-10-25 | |
| US81783806P | 2006-06-30 | 2006-06-30 | |
| PCT/IB2006/003843 WO2007049155A2 (en) | 2005-10-25 | 2006-10-25 | Compositions comprising yersinia pestis antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515831A JP2009515831A (ja) | 2009-04-16 |
| JP2009515831A5 true JP2009515831A5 (enExample) | 2010-11-11 |
Family
ID=37968196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008537233A Pending JP2009515831A (ja) | 2005-10-25 | 2006-10-25 | ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7776336B2 (enExample) |
| EP (1) | EP1954306A2 (enExample) |
| JP (1) | JP2009515831A (enExample) |
| AU (1) | AU2006307602A1 (enExample) |
| CA (1) | CA2627302A1 (enExample) |
| WO (1) | WO2007049155A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| GB0525213D0 (en) * | 2005-12-12 | 2006-01-18 | Secr Defence | Vaccine |
| US10174100B1 (en) * | 2006-11-06 | 2019-01-08 | Microvax, Llc | Multivalent DNA composition for Yersinia pestis |
| GB0717187D0 (en) * | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
| WO2010117455A2 (en) * | 2009-04-08 | 2010-10-14 | U.S. Army Medical Research Institute Of Infectious Diseases | Human monoclonal antibodies protective against bubonic plaque |
| ITMI20090946A1 (it) | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
| CA2781645A1 (en) * | 2009-11-24 | 2011-06-03 | Inviragen, Inc. | Compositions, methods and uses for expression of enterobacterium-associated peptides |
| PL3243526T3 (pl) | 2010-07-06 | 2020-05-18 | Glaxosmithkline Biologicals S.A. | Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| FI4005592T3 (fi) | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| HUE061068T2 (hu) | 2010-08-31 | 2023-05-28 | Glaxosmithkline Biologicals Sa | Pegilált liposzómák immunogént kódoló RNS szállítására |
| EP4098324A1 (en) | 2010-10-11 | 2022-12-07 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| US10286056B2 (en) | 2011-01-27 | 2019-05-14 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with crystallisation inhibitors |
| EP2688590B1 (en) | 2011-03-24 | 2020-02-12 | GlaxoSmithKline Biologicals SA | Adjuvant nanoemulsions with phospholipids |
| CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| EP2750707B1 (en) | 2011-08-31 | 2018-10-24 | GlaxoSmithKline Biologicals SA | Pegylated liposomes for delivery of immunogen-encoding rna |
| CA2882382A1 (en) | 2012-09-18 | 2014-03-27 | Novartis Ag | Outer membrane vesicles |
| WO2014136086A1 (en) | 2013-03-08 | 2014-09-12 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US10342761B2 (en) | 2014-07-16 | 2019-07-09 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| US10125092B2 (en) | 2014-09-05 | 2018-11-13 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| WO2022081750A1 (en) | 2020-10-14 | 2022-04-21 | George Mason Research Foundation, Inc. | Ionizable lipids and methods of manufacture and use thereof |
| CN112609013A (zh) * | 2021-01-12 | 2021-04-06 | 深圳市赛格诺生物科技有限公司 | 一种用于检测鼠疫耶尔森菌的荧光pcr试剂及方法 |
| WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0525213D0 (en) | 2005-12-12 | 2006-01-18 | Secr Defence | Vaccine |
-
2006
- 2006-10-25 EP EP06831828A patent/EP1954306A2/en not_active Withdrawn
- 2006-10-25 AU AU2006307602A patent/AU2006307602A1/en not_active Abandoned
- 2006-10-25 US US12/091,604 patent/US7776336B2/en not_active Expired - Fee Related
- 2006-10-25 CA CA002627302A patent/CA2627302A1/en not_active Abandoned
- 2006-10-25 JP JP2008537233A patent/JP2009515831A/ja active Pending
- 2006-10-25 WO PCT/IB2006/003843 patent/WO2007049155A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515831A5 (enExample) | ||
| Shin et al. | COVID-19 vaccine development and a potential nanomaterial path forward | |
| JP2012501959A5 (enExample) | ||
| JP2006526414A5 (enExample) | ||
| DE60329106D1 (de) | Ghrelin-träger-konjugate | |
| JP2010162023A5 (enExample) | ||
| WO2006045796A3 (en) | Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof | |
| JP2010524489A5 (enExample) | ||
| WO2006063974A3 (en) | Il-15 antigen arrays and uses thereof | |
| DK1443960T3 (da) | Antigen-arrays der betegner IL-5, IL-13 eller eotaxin til behandling af allergiske eosinofile sygdomme | |
| CN1610697A (zh) | 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途 | |
| AU2003246373A8 (en) | Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions | |
| JP2009504654A5 (enExample) | ||
| WO2003039225A3 (en) | Antigen arrays comprising rankl for treatment of bone disease | |
| JP2011517938A5 (enExample) | ||
| JP2010532656A5 (enExample) | ||
| Kovalenko et al. | Vaccine candidate against COVID-19 based on structurally modified plant virus as an adjuvant | |
| JP2010506926A5 (enExample) | ||
| JP2002534481A5 (enExample) | ||
| JP2015529677A5 (enExample) | ||
| WO2001096370A3 (en) | Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof | |
| Nuzzaci et al. | In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine | |
| JP2006523185A5 (enExample) | ||
| CN102464721B (zh) | 针对人肠道病毒71型的重组广谱性疫苗 | |
| WO2003059386A3 (en) | Prion protein carrier-conjugates |